1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsThis program provides a tax offset for eligible research and development (R&D) activities conducted in Australia. While not a direct grant, it offers significant financial support for innovation. R&D activities conducted overseas are eligible under certain circumstances.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: Companies investing in eligible research and development activities in Australia. Refundable offset for companies with turnover under $20 million; tiered intensity system for larger companies. Confirm the full requirements in the official notice before applying.
The current listing shows tax offset (43.5% refundable for companies with turnover under $20M, or 38.5% non-refundable for larger companies). Verify award ceilings, matching requirements, and allowable costs in the official notice.
Research & Development Tax Incentive is funded by Australian Taxation Office (ATO) and AusIndustry (Department of Industry, Science and Resources). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
The Merck Stimulating Innovative Research Grant Program 2026 includes a dedicated grant topic for artificial intelligence in cell culture media and process development, offering up to EUR 150,000 per year for up to 3 years. The program accelerates innovation through collaborative research, early engagement with industry experts, and translation of novel ideas into practical solutions. In 2026, priority areas also include in-vitro models for neuroinflammatory diseases (EUR 250,000/year for 2 years) and innovative approaches to contaminated materials remediation (EUR 150,000/year for 2 years). The two-stage application process begins with non-confidential submissions, followed by deep-dive workshops where finalists collaborate with Merck scientists and managers to jointly optimize proposals. The AI-specific grant focuses on applying machine learning and AI to optimize cell culture media formulation, bioprocess parameter optimization, and manufacturing quality control.
Summary: The fiscal year 2026 (FY26) Duchenne Muscular Dystrophy Research Program (DMDRP) Idea Development Award (IDA) promotes new ideas that are still in the early stages of development and have the potential to yield impactful data and new avenues of investigation. This award supports impactful, high-risk/high-reward research that could lead to critical discoveries or major advancements that will accelerate progress in improving outcomes for individuals with Duchenne muscular dystrophy (DMD) in the near term. Applications should include a well-formulated, testable hypothesis based on strong scientific rationale. The DMDRP strongly encourages research projects investigating therapies designed to demonstrate efficacy cross the life span, including infants, toddlers and nonambulatory individuals.Distinctive Features: The FY26 DMDRP IDA mechanism offers three eligibility career categories:• The Established Investigator category is for independent investigators at all academic levels, or equivalent• The New Investigator – Early-Stage category is for independent investigators early in their careers (i.e., within 10 years of their first faculty appointment or equivalent). Applicants in this category will be reviewed separately from Established Investigators.• The New Investigator – Transitioning category is for independent investigators at all academic levels, or equivalent, in an area other than muscular dystrophy who are seeking to transition to a career in DMD, thereby bringing their expertise to the field. Applicants in this category will be reviewed separately from Established Investigators.Preliminary data relevant to DMD that supports the feasibility of the research hypotheses and research approaches are required for all applications. Clinical trials or clinical trial aims are not allowed. Funding Opportunity Number: HT942526DMDRPIDA. Assistance Listing: 12.420. Funding Instrument: G. Category: ST. Award Amount: $2.5M total program funding.
On August 26, 2026, NSF named the STC class of 2026: TEMPEST at Michigan State, GENIE at Northwestern, and a human-robot co-adaptation center at UT Austin. $90 million total, $6 million a year each. The 2023 class was four centers and $120 million. The award size is intact; the shelf space shrank 25 percent — and that is the number that should reshape how you plan a center proposal.
Read articleNSF's Industry-Integrated PhD Scholars Program commits $47 million over five years through the nonprofit UIDP to place more than 250 doctoral students in year-long industry research placements. Universities fund year one, NSF funds years two through four, and each company puts in at least $100,000 per student. Here is what the funding structure actually selects for, the four-year timeline problem, and what universities, companies, and students should do.
Read articleNIH published its 'what we heard' summary on the proposed cap on simultaneous Research Project Grants in August 2026. A four-RPG cap would free $1.3 billion for about 1,900 additional investigators; a two-RPG cap would free roughly $3.5 billion for about 5,200. Respondents overwhelmingly proposed alternatives. Here is what the comment record actually says, what NIH signaled about next steps, and how PIs and research offices should position before a policy notice lands.
Read article